Holen Sie sich die Stockscreener-App
13.04
0.23%
-0.03
Schlusskurs vom Vortag:
$13.07
Offen:
$13.32
24-Stunden-Volumen:
92,895
Relative Volume:
0.84
Marktkapitalisierung:
$487.96M
Einnahmen:
$239.40M
Nettoeinkommen (Verlust:
$104.44M
KGV:
4.4054
EPS:
2.96
Netto-Cashflow:
$-18.50M
1W Leistung:
-2.98%
1M Leistung:
-0.15%
6M Leistung:
-20.78%
1J Leistung:
-1.95%
1-Tages-Spanne:
$12.97
$13.40
1-Wochen-Bereich:
$12.70
$13.62
52-Wochen-Spanne:
$11.35
$21.79
Entrada Therapeutics Inc Stock (TRDA) Company Profile
Firmenname
Entrada Therapeutics Inc
Sektor
Branche
Telefon
857-305-1825
Adresse
ONE DESIGN CENTER PLACE, BOSTON
Vergleichen Sie TRDA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TRDA
Entrada Therapeutics Inc
|
13.04 | 487.96M | 239.40M | 104.44M | -18.50M | 2.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Entrada Therapeutics Inc Stock (TRDA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-06 | Eingeleitet | ROTH MKM | Buy |
| 2024-01-05 | Eingeleitet | Oppenheimer | Outperform |
| 2023-04-03 | Eingeleitet | H.C. Wainwright | Buy |
Entrada Therapeutics Inc Aktie (TRDA) Neueste Nachrichten
H.C. Wainwright maintains $20 target on Entrada Therapeutics stock - MSN
Trading (TRDA) With Integrated Risk Controls - Stock Traders Daily
Entrada Therapeutics: Cash-Rich Innovator With Asymmetric Upside - Seeking Alpha
Entrada Therapeutics, Inc. (TRDA): A Cheap Biotech Stock to Invest In Now - Insider Monkey
10 Cheap Biotech Stocks to Invest in Now - Insider Monkey
How the (TRDA) price action is used to our Advantage - Stock Traders Daily
Entrada Shorted Ohio State Affiliate $20 Million Fees, Suit Says - Bloomberg Law
Entrada Therapeutics (NASDAQ:TRDA) Receives Buy Rating from HC Wainwright - MarketBeat
SG Americas Securities LLC Has $243,000 Stock Position in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - Defense World
BlackRock, Inc. Increases Stake in Entrada Therapeutics Inc - GuruFocus.com
Entrada Therapeutics advances Duchenne treatment study - MSN
Entrada Therapeutics Inc.: Promising Therapeutic Potential and Favorable Valuation Amidst Risks - TipRanks
ENTR-601-44 Trial For DMD Authorized In UK, Study Launch Expected In Q2 2025 - Nasdaq
Entrada Therapeutics Gets UK Approval for Phase 1/2 Study of Duchenne Muscular Dystrophy Treatment - Marketscreener.com
Entrada Therapeutics Advances Duchenne Muscular Dystrophy Trial - TipRanks
Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-44-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-44 in Patients Living with Duchenne Muscular Dystrophy - The Manila Times
Duchenne Muscular Dystrophy Breakthrough: Entrada's Novel Treatment Advances After Promising Safety Results - StockTitan
Azenta Announces the Election of Dipal Doshi to its Board of Directors - PR Newswire
(TRDA) Proactive Strategies - Stock Traders Daily
Pompe Disease Pipeline 2024: Mechanism of Action, Route of Administration, and Clinical Trial Insights Explored by DelveInsight | M6P Therapeutics, Entrada Therapeutics, Maze Therapeutics, Astellas - The Globe and Mail
When (TRDA) Moves Investors should Listen - Stock Traders Daily
Barclays PLC Buys 30,585 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) - Defense World
Barclays PLC Acquires 30,585 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) - MarketBeat
Entrada Therapeutics : Corporate Presentation -January 15, 2025 at 04:41 pm EST - Marketscreener.com
Entrada Therapeutics, Inc. (NASDAQ:TRDA) Shares Sold by Jane Street Group LLC - Defense World
The Market Doesn't Like What It Sees From Entrada Therapeutics, Inc.'s (NASDAQ:TRDA) Revenues Yet As Shares Tumble 26% - Simply Wall St
Entrada Therapeutics (NASDAQ:TRDA) Trading Down 7.6%Here's Why - MarketBeat
Alltrna Appoints Dr. Nerissa Kreher as Chief Medical Officer to Advance tRNA Medicines for Rare Diseases - PR Newswire
Geode Capital Management LLC Raises Position in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - MarketBeat
Geode Capital Management LLC Has $9.21 Million Stake in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - Defense World
Barclays PLC Increases Holdings in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - Defense World
Entrada Therapeutics, Inc. (NASDAQ:TRDA) Shares Bought by Barclays PLC - MarketBeat
Best Momentum Stocks to Buy for December 30th - Yahoo Finance
State Street Corp Has $7.50 Million Stock Position in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - Defense World
Where are the Opportunities in (TRDA) - Stock Traders Daily
Entrada Therapeutics, Inc. (NASDAQ:TRDA) Shares Bought by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - Defense World
Entrada Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - Marketscreener.com
Recent Price Trend in Entrada Therapeutics (TRDA) is Your Friend, Here's Why - MSN
Charles Schwab Investment Management Inc. Has $2.97 Million Position in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - Defense World
XTX Topco Ltd Takes $634,000 Position in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - MarketBeat
Entrada Therapeutics, Inc. (NASDAQ:TRDA) Shares Sold by Fmr LLC - MarketBeat
Is Entrada Therapeutics, Inc.'s (NASDAQ:TRDA) Recent Stock Performance Tethered To Its Strong Fundamentals? - Simply Wall St
Entrada Therapeutics (NASDAQ:TRDA) Upgraded at Roth Capital - Defense World
Roth Mkm Begins Coverage on Entrada Therapeutics (NASDAQ:TRDA) - MarketBeat
Roth MKM starts ‘overlooked’ Entrada Therapeutics with Buy rating - Yahoo Finance
Entrada Therapeutics, Inc. (NASDAQ:TRDA) Shares Purchased by Janus Henderson Group PLC - MarketBeat
Jacobs Levy Equity Management Inc. Has $3.23 Million Stock Position in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - MarketBeat
Finanzdaten der Entrada Therapeutics Inc-Aktie (TRDA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Entrada Therapeutics Inc-Aktie (TRDA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| MPM BIOVENTURES 2018, L.P. | 10% Owner |
Dec 11 '24 |
Sale |
20.23 |
21,787 |
440,751 |
4,381,062 |
| MPM BioVentures 2014, L.P. | 10% Owner |
Dec 10 '24 |
Sale |
20.77 |
22,935 |
476,360 |
4,402,849 |
| MPM BioVentures 2014, L.P. | 10% Owner |
Dec 11 '24 |
Sale |
20.23 |
21,787 |
440,751 |
4,381,062 |
| WENTWORTH KORY JAMES | Chief Financial Officer |
Dec 02 '24 |
Option Exercise |
2.10 |
5,000 |
10,500 |
78,849 |
| WENTWORTH KORY JAMES | Chief Financial Officer |
Nov 29 '24 |
Option Exercise |
2.10 |
1,000 |
2,100 |
74,849 |
| WENTWORTH KORY JAMES | Chief Financial Officer |
Dec 02 '24 |
Sale |
20.00 |
5,000 |
99,978 |
73,849 |
| WENTWORTH KORY JAMES | Chief Financial Officer |
Nov 29 '24 |
Sale |
19.97 |
1,000 |
19,970 |
73,849 |
| Sethuraman Natarajan | President, Research & Develop. |
Dec 03 '24 |
Sale |
20.15 |
11,703 |
235,786 |
144,997 |
| Sethuraman Natarajan | President, Research & Develop. |
Dec 02 '24 |
Sale |
20.26 |
4,088 |
82,834 |
156,700 |
| Sethuraman Natarajan | President, Research & Develop. |
Nov 29 '24 |
Sale |
20.00 |
100 |
2,000 |
160,788 |
0.27%
3.05%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):